Eyepoint Pharmaceuticals (NASDAQ:EYPT) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Eyepoint Pharmaceuticals (NASDAQ:EYPT) announced its quarterly earnings results on Wednesday. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.03), reports. The business had revenue of $0.62 million for the quarter, compared to analysts’ expectations of $1.01 million. Eyepoint Pharmaceuticals had a negative net margin of 485.95% and a negative return on equity of 76.13%.

Here are the key takeaways from Eyepoint Pharmaceuticals’ conference call:

• DURAVYU Phase 3 wet AMD program on track — the LUGANO and LUCIA trials are progressing and the company expects top-line data beginning in mid?2026, using an on?label aflibercept comparator with planned superiority testing on treatment burden and 6?month redosing.
• DME pivotal program initiated — first patients have been dosed in the two Phase 3 DME trials (COMO and CAPRI), with randomization underway, rapid enrollment expected via existing site network, and top?line data targeted in H2 2027.
• Strong cash runway — cash and investments of $306 million (after a $173 million follow?on in Oct 2025) are expected to fund operations into Q4 2027, supporting Phase 3 programs and NDA preparation.
• Rising costs and wider losses — operating expenses increased materially (Q4 2025: $71M vs $57M; FY 2025: $275M vs $189M) driven by Phase 3 activity, and FY net loss widened to $232M, while revenue declined due to prior deferred revenue recognition.
• Favorable safety and differentiated MOA — in >190 treated patients DURAVYU has shown no ocular/systemic SAEs attributed to the drug, low rates of cataracts (~5.8%), floaters (~5.2%) and ~1% intraocular inflammation, and the company emphasizes a multi?MOA (VEGF/PDGF/IL?6 via JAK1) sustained?release profile aimed at 6?month dosing.

Eyepoint Pharmaceuticals Trading Down 8.9%

NASDAQ:EYPT traded down $1.60 during trading hours on Thursday, reaching $16.40. 928,559 shares of the company traded hands, compared to its average volume of 1,407,387. The business’s 50-day moving average price is $15.76 and its two-hundred day moving average price is $14.31. Eyepoint Pharmaceuticals has a 1 year low of $3.91 and a 1 year high of $19.11. The stock has a market capitalization of $1.36 billion, a P/E ratio of -5.48 and a beta of 1.72.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on EYPT shares. Cantor Fitzgerald raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, November 25th. TD Cowen raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Thursday, January 22nd. HC Wainwright lifted their target price on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Chardan Capital increased their price target on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Eyepoint Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $31.50.

Key Stories Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target to $30 and kept a “buy” rating, implying meaningful upside vs. current levels — a catalyst for bullish investor flows. Article Title
• Positive Sentiment: Chardan Capital also raised its target (to $29) and reiterated a “buy,” reinforcing analyst optimism and supporting positive sentiment among growth/biotech investors. Benzinga TickerReport
• Positive Sentiment: Pipeline progress: EyePoint says both pivotal Phase 3 trials for DURAVYU in wet AMD are on track and topline data for DURAVYU (wet AMD and DME) is targeted mid-2026 — a major binary value driver if readouts are positive. Article
• Positive Sentiment: Commercial and balance-sheet setup: company appointed a Chief Commercial Officer to lead launch readiness for DURAVYU and reported >$300M cash & investments as of 12/31/25, giving runway into Q4 2027 — reduces near-term financing risk ahead of pivotal readouts. Press Release
• Neutral Sentiment: Company released Q4 and full-year 2025 results and hosted an earnings call; transcripts are available for detail on guidance, ops and R&D cadence. These provide color but no new surprise beyond the headline miss. Press Release/Transcript Transcript
• Neutral Sentiment: Reported short-interest data in feeds is inconsistent/zeroed out (likely a reporting artifact), so it appears not to be a current driver of volatility. (No link provided.)
• Negative Sentiment: Earnings miss: Q4 EPS of ($0.81) missed consensus (~$0.78) and revenue ($0.62M) fell short of estimates (~$1.01M), reinforcing that EyePoint remains pre-commercial and loss-making until DURAVYU approval/commercialization. Earnings Zacks
• Negative Sentiment: Critical perspective: a Seeking Alpha piece argues the “pre-readout” rally may overlook commercial execution risks and a tougher-than-expected market environment — a narrative that can pressure sentiment among more cautious investors. Seeking Alpha

Insider Buying and Selling at Eyepoint Pharmaceuticals

In other news, insider Ramiro Ribeiro sold 42,544 shares of Eyepoint Pharmaceuticals stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $17.10, for a total value of $727,502.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.46% of the stock is owned by insiders.

Institutional Trading of Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of EYPT. Russell Investments Group Ltd. bought a new position in shares of Eyepoint Pharmaceuticals in the third quarter worth approximately $76,000. Tower Research Capital LLC TRC lifted its position in Eyepoint Pharmaceuticals by 218.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after acquiring an additional 5,967 shares in the last quarter. California State Teachers Retirement System boosted its stake in Eyepoint Pharmaceuticals by 20.6% during the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after purchasing an additional 794 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in shares of Eyepoint Pharmaceuticals in the 4th quarter worth $98,000. Finally, Raymond James Financial Inc. raised its stake in shares of Eyepoint Pharmaceuticals by 11.0% in the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after purchasing an additional 1,177 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.